-
For its part, Merck notes that its BACE inhibitor recently demonstrated a reduction in cerebral spinal fluid, or CSF, a biomarker, in a Phase I study.
FORBES: Merck Makes A 'Speculative' Step Into Alzheimer's
-
So why does this tiny Phase I pilot study, successful for only four of six women, matter so much?
FORBES: Startling Treatment Breakthrough For Anorexia Leads To New Understanding Of Brain Disorders
-
The company recently completed enrollment in a Phase I clinical study of MultiStem in heart attack patients, and is midway through a clinical study of MultiStem in leukemia and other cancer patients.
FORBES
-
The treatment, CYT387, appears to demonstrate an ability to render and maintain myelofibrosis patients transfusion independent for clinically-relevant periods, while also improving other symptoms, according to a phase I and phase II study.
FORBES: Pharma News: Alexza Pharmaceuticals, YM BioSciences